Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRTX NASDAQ:KRON NASDAQ:MCRB NASDAQ:TRDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.24-1.6%$1.61$1.04▼$2.68$230.98M1.231.44 million shs963,820 shsKRONKronos Bio$0.88+1.5%$0.81$0.65▼$1.46$53.72M1.64370,931 shs54,089 shsMCRBSeres Therapeutics$15.69-1.4%$15.92$6.53▼$24.67$139.29M0.15243,749 shs151,689 shsTRDAEntrada Therapeutics$5.06-4.2%$5.83$4.93▼$21.79$200.84M-0.13216,877 shs220,852 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%KRONKronos Bio0.00%0.00%0.00%-0.85%-7.37%MCRBSeres Therapeutics0.00%-17.82%-4.67%+112.13%-20.39%TRDAEntrada Therapeutics0.00%-0.19%+0.19%-28.74%-64.80%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRTXHeron Therapeutics$1.24-1.6%$1.61$1.04▼$2.68$230.98M1.231.44 million shs963,820 shsKRONKronos Bio$0.88+1.5%$0.81$0.65▼$1.46$53.72M1.64370,931 shs54,089 shsMCRBSeres Therapeutics$15.69-1.4%$15.92$6.53▼$24.67$139.29M0.15243,749 shs151,689 shsTRDAEntrada Therapeutics$5.06-4.2%$5.83$4.93▼$21.79$200.84M-0.13216,877 shs220,852 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRTXHeron Therapeutics0.00%-3.82%-5.26%-37.93%-32.62%KRONKronos Bio0.00%0.00%0.00%-0.85%-7.37%MCRBSeres Therapeutics0.00%-17.82%-4.67%+112.13%-20.39%TRDAEntrada Therapeutics0.00%-0.19%+0.19%-28.74%-64.80%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRTXHeron Therapeutics 2.33Hold$4.50262.90% UpsideKRONKronos Bio 2.00Hold$1.0013.64% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67369.51% UpsideTRDAEntrada Therapeutics 3.00Buy$25.67407.25% UpsideCurrent Analyst Ratings BreakdownLatest KRON, MCRB, HRTX, and TRDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025HRTXHeron TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025HRTXHeron TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$4.00 ➝ $3.008/8/2025TRDAEntrada TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRTXHeron Therapeutics$144.29M1.58N/AN/A($0.22) per share-5.64KRONKronos Bio$9.85M5.45N/AN/A$1.45 per share0.61MCRBSeres Therapeutics$126.32M1.09N/AN/A$1.61 per share9.75TRDAEntrada Therapeutics$210.78M0.91$1.52 per share3.33$11.46 per share0.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRTXHeron Therapeutics-$13.58M-$0.02N/AN/AN/A-0.62%N/A-0.40%11/11/2025 (Estimated)KRONKronos Bio-$86.08M-$1.07N/AN/AN/A-701.53%-64.22%-47.17%N/AMCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)TRDAEntrada Therapeutics$65.63M-$1.78N/AN/AN/A-92.30%-17.81%-14.55%11/4/2025 (Estimated)Latest KRON, MCRB, HRTX, and TRDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025HRTXHeron Therapeutics-$0.01-$0.02-$0.01-$0.02$38.08 million$37.20 million8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/A8/6/2025Q2 2025TRDAEntrada Therapeutics-$0.86-$1.04-$0.18-$1.04$8.17 million$1.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRTXHeron TherapeuticsN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ATRDAEntrada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRTXHeron TherapeuticsN/A0.820.53KRONKronos BioN/A12.9312.93MCRBSeres TherapeuticsN/A1.571.57TRDAEntrada TherapeuticsN/A18.6418.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRTXHeron Therapeutics80.01%KRONKronos Bio64.09%MCRBSeres Therapeutics59.34%TRDAEntrada Therapeutics86.39%Insider OwnershipCompanyInsider OwnershipHRTXHeron Therapeutics5.86%KRONKronos Bio24.40%MCRBSeres Therapeutics4.70%TRDAEntrada Therapeutics7.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRTXHeron Therapeutics300183.32 million172.57 millionOptionableKRONKronos Bio10061.05 million46.16 millionOptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionableTRDAEntrada Therapeutics11038.04 million35.15 millionOptionableKRON, MCRB, HRTX, and TRDA HeadlinesRecent News About These CompaniesBrokerages Set Entrada Therapeutics, Inc. (NASDAQ:TRDA) PT at $25.67September 14 at 2:34 AM | americanbankingnews.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Given Consensus Rating of "Buy" by BrokeragesSeptember 11, 2025 | marketbeat.comNuveen LLC Purchases Shares of 67,016 Entrada Therapeutics, Inc. $TRDASeptember 6, 2025 | marketbeat.comEntrada Therapeutics Announces Recipients of Third Annual DREAMS Grant ProgramSeptember 5, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 2, 2025 | globenewswire.comMerck & Co. Inc. Takes Position in Entrada Therapeutics, Inc. $TRDAAugust 26, 2025 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Sells 74,068 Shares of Entrada Therapeutics, Inc. $TRDAAugust 23, 2025 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Buy" from BrokeragesAugust 17, 2025 | marketbeat.comEntrada (TRDA) Q2 Revenue Drops 98%August 11, 2025 | theglobeandmail.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To KnowAugust 9, 2025 | finance.yahoo.comEntrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue EstimatesAugust 6, 2025 | zacks.comEntrada Therapeutics Reports Second Quarter 2025 Financial ResultsAugust 6, 2025 | globenewswire.comEntrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?July 31, 2025 | zacks.com5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202kJuly 13, 2025 | investing.comEntrada therapeutics (TRDA) director Parmar sells $202k in stockJuly 13, 2025 | investing.comVentures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockJuly 12, 2025 | insidertrades.comEntrada Therapeutics (TRDA) 10% owners sell $866k in stockJuly 3, 2025 | investing.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 SharesJuly 2, 2025 | insidertrades.comEntrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of DirectorsJune 3, 2025 | globenewswire.comEntrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2, 2025 | globenewswire.comEntrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...May 29, 2025 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRON, MCRB, HRTX, and TRDA Company DescriptionsHeron Therapeutics NASDAQ:HRTX$1.24 -0.02 (-1.59%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.01 (+0.40%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.Kronos Bio NASDAQ:KRONKronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Seres Therapeutics NASDAQ:MCRB$15.69 -0.22 (-1.38%) Closing price 04:00 PM EasternExtended Trading$15.50 -0.18 (-1.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Entrada Therapeutics NASDAQ:TRDA$5.06 -0.22 (-4.17%) Closing price 04:00 PM EasternExtended Trading$5.05 -0.01 (-0.20%) As of 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
